Erratum to: Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy

[1]  F. López-Ríos,et al.  A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. , 2014, Cancer letters.

[2]  L. Shen,et al.  Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients. , 2014, Biomarkers in medicine.

[3]  R. Kurzrock,et al.  HER2 aberrations in cancer: implications for therapy. , 2014, Cancer treatment reviews.

[4]  D. Ilson,et al.  HER2 Directed Therapy for Gastric/Esophageal Cancers , 2014, Current Treatment Options in Oncology.

[5]  H. Seol,et al.  Serum human epidermal growth factor receptor 2 levels as a real‐time marker for tumor burden in breast cancer patients , 2014, Journal of surgical oncology.

[6]  M. Hidalgo,et al.  Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  I. Brandslund,et al.  Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer , 2013, Clinical chemistry and laboratory medicine.

[8]  T. Narita,et al.  Status of tissue expression and serum levels of HER2 in gastric cancer patients in Japan. , 2013, Hepato-Gastroenterology.

[9]  X. An,et al.  Serum HER 2 Extracellular Domain Level Is Correlated with Tissue HER 2 Status in Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma , 2013, PloS one.

[10]  N. Boku.  HER2-positive gastric cancer , 2013, Gastric Cancer.

[11]  Hongtao Zhang,et al.  Challenges in the clinical utility of the serum test for HER2 ECD. , 2012, Biochimica et biophysica acta.

[12]  M. Campiglio,et al.  Activity and resistance of trastuzumab according to different clinical settings. , 2012, Cancer treatment reviews.

[13]  B. Leyland-Jones,et al.  Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. , 2011, The Lancet. Oncology.

[14]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[15]  H. Tesch,et al.  Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial , 2010, Breast Cancer Research and Treatment.

[16]  F. Esteva,et al.  Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancer , 2008, Cancer.

[17]  B. Ljung,et al.  HER2 testing in breast cancer: NCCN Task Force report and recommendations. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  C. Hudis,et al.  Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J. Baselga,et al.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.

[20]  J. Kinoshita,et al.  Erratum to: Evaluation of serum HER2-ECD levels in patients with gastric cancer , 2014, Journal of gastroenterology.

[21]  J. Kinoshita,et al.  Evaluation of serum HER2-ECD levels in patients with gastric cancer , 2014, Journal of Gastroenterology.